High HOTAIRM1 expression identified a subset of patients with worse outcome both in the overall series of 215 IR-AML patients and within molecular prognostic categories as defined by NPM1, FLT3-ITD and CEBPA mutational status. This evidence concerns the gene HOTAIRM1 and acute myeloid leukemia.